Ms. Grammel has worked on matters progressing to jury and bench trial in the Southern District of New York, the District of Delaware, the District of Massachusetts and the Eastern District of Missouri. She has also worked on appellate matters in the First Circuit and the Supreme Judicial Court of Massachusetts.
Representative matters include:
- Reckitt Benckiser Pharmaceuticals Inc. et al. v. Teva Pharmaceuticals USA, Inc., No. 14-1451-RGA (D. Del.). Representing Teva in Hatch-Waxman suit brought by Reckitt in response to Teva’s Abbreviated New Drug Application seeking approval to market a generic version of SUBOXONE® (buprenorphine/naloxone) sublingual films. Asserted patents included formulation and process claims.
- AstraZeneca Pharmaceuticals LP et al. v. Teva Pharmaceuticals USA, Inc., No. 14-1478-GMS (D. Del.). Representing Teva in Hatch-Waxman suit brought by AstraZeneca in response to Teva’s Abbreviated New Drug Application seeking approval to market a generic version of BYETTA® (exenatide). Asserted patents included formulation and method of treatment claims.
- Veracode, Inc. et al v. Appthority, Inc. (D. Mass.). Representing patent owner asserting patents relating to source code analysis and review in jury trial and post-trial proceedings.
In addition to her IP work, Ms. Grammel was one of the Goodwin attorneys working on the criminal trial defense of former SAC Capital Advisors portfolio manager Mathew Martoma against criminal and SEC allegations of insider trading. Prosecutors alleged that Martoma participated in the largest-ever insider trading case, committing securities fraud by trading on shares of two pharmaceutical companies using non-public information, resulting in over $276 million in gains.
Ms. Grammel is a member of the Boston Bar Association, the American Bar Association and the National Association of Women Lawyers.